Catalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for ACTengine® IMA203CD8 GEN2 (PRAME) in Synovial Sarcoma. The expected timing is based on the latest available company guidance and may change.
05/30/26:- Ph1 NCT03686124 synovial sarcoma data: ORR 67%, cORR 64%; durability follow-up update planned H2 2026. 07/17/26:- ESMO 2026 Phase 1 IMA203CD8 results abstract Oct 19; oral Oct 23, 2026. 08/18/26:- Phase 1 synovial sarcoma data showed 67% response rate. Updated solid-tumor data will be presented at ESMO 2026.
Verification
Confirm timing and program details against the company announcement or filing.